CSLLY — CSL LTD
—
OTC ·
Unknown ·
Unknown ·
CIK 1274152 ·
Last close
$24.28
Market Cap
$46.51B
52W High
$24.72
52W Low
$16.01
ADV30
252,747
Next earnings
2026-08-17
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 8,213,000,000 | 4,279,000,000 | 1,977,000,000 | 2,007,000,000 | 38,447,000,000 | 1,524,000,000 | 17,901,000,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$17,331,000,000
Inventory
$6,139,000,000
Receivables
$3,606,000,000
ST Investments
—
EBIT TTM
$2,753,000,000
Pretax Income TTM
$2,540,000,000
Interest Exp TTM
$213,000,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,406,999,552
EBITDA
$4,840,000,000
Free Cash Flow
$1,848,125,056
Enterprise Value
$58,484,547,584
Total Cash
$1,144,999,936
Total Debt
$11,137,999,872
Shares Out
1,915,647,916
Trailing EPS
$1.53
Book Value
$9.67
ROE
6.7%
ROA
6.6%
Div Yield
2.96%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 15,430,000,000 | 2,959,000,000 | 3,002,000,000 | 39,404,000,000 | 17,997,000,000 | — | — |
| Jun 2024 | 14,690,000,000 | 2,764,000,000 | 2,642,000,000 | 38,022,000,000 | 18,621,000,000 | — | — |
| Jun 2023 | 13,174,000,000 | 2,102,000,000 | 2,194,000,000 | 36,234,000,000 | 18,408,000,000 | — | — |
| Jun 2022 | 10,493,100,000 | 2,316,100,000 | 2,254,700,000 | 28,346,000,000 | 13,768,500,000 | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMXHF | CSL LTD | $46.95B | $98.03 | — |
| TRI | THOMSON REUTERS CORP /CAN/ | $45.95B | $106.07 | — |
| RKLB | Rocket Lab Corp | $47.94B | $80.10 | — |
| PAYX | PAYCHEX INC | $44.60B | $125.40 | — |
| GDERF | Galderma Group AG/ADR | $49.13B | $210.70 | — |
News headlines (Yahoo Finance, 1h cache)
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
2026-07-27 13:00 · Yahoo
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
2026-06-26 13:00 · Yahoo
Should Value Investors Buy CSL Limited (CSLLY) Stock?
2026-05-04 13:40 · Yahoo
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
2026-04-30 15:40 · Yahoo
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
2026-04-14 15:40 · Yahoo
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
2026-05-20 10:00 · Yahoo
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
2026-03-06 14:00 · Yahoo
Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
2026-02-18 11:15 · Yahoo
There May Be Some Bright Spots In CSL's (ASX:CSL) Earnings
2026-02-17 04:31 · Yahoo
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
2026-02-16 16:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.